Dimension

Team Portfolio Research Perspectives

Manifesto Team Portfolio Research Perspectives

Odyssey Therapeutics

Next generation precision medicines for cancer and inflammatory diseases

Odyssey Therapeutics

Odyssey leverages deep immunobiology, medicinal chemistry, and genetics expertise to create innovative therapies for inflammatory and autoimmune conditions

Founders

Chief Executive Officer

Gary Glick

In The News

Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio

Odyssey gets $213M Series D after backing out of IPO

Our Thoughts

Partnering with Odyssey Therapeutics

Sign up for dispatches from the frontier of what’s possible.

Email Address

The email you entered is invalid

Thank you! Your submission has been received.

Oops! Something went wrong while submitting the form.

Contact careers Privacy Terms & conditions

© Dimension 2024

Sign up for dispatches from the frontier of what’s possible.

Email Address

The email you entered is invalid

Thank you! Your submission has been received.

Oops! Something went wrong while submitting the form.

Contact careers Privacy Terms & conditions

© Dimension 2025

Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio

Odyssey gets $213M Series D after backing out of IPO